NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $4.81 -0.07 (-1.43%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$4.88 +0.07 (+1.46%) As of 09/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aquestive Therapeutics Stock (NASDAQ:AQST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$4.76▼$4.9050-Day Range$3.60▼$5.3952-Week Range$2.93▼$7.55Volume1.61 million shsAverage Volume2.90 million shsMarket Capitalization$603.70 millionP/E RatioN/ADividend YieldN/APrice Target$9.17Consensus RatingModerate Buy Company Overview Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration. Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome. The company also maintains a pipeline of products based on its film-delivery technology, including therapies intended for emergency and central nervous system applications. The company was previously known as MonoSol Rx and adopted the Aquestive Therapeutics name in 2018. It is headquartered in Warren, New Jersey, and serves the U.S. market through its commercial operations while pursuing licensing and collaboration opportunities to support international availability. Daniel A. Barber has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 531st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAquestive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAquestive Therapeutics has a consensus price target of $9.17, representing about 90.6% upside from its current price of $4.81.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Aquestive Therapeutics are expected to remain at ($0.50) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.78% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 7.15.Change versus previous monthShort interest in Aquestive Therapeutics has recently increased by 21.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentAquestive Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aquestive Therapeutics this week, compared to 7 articles on an average week.Search Interest5 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows6 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,175.00 in company stock.Percentage Held by Insiders6.81% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by Institutions32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQST Stock News HeadlinesAquestive Therapeutics (NASDAQ:AQST) Stock Price Down 4.5% on Insider SellingSeptember 13 at 4:53 AM | americanbankingnews.comInsider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells 8,750 SharesSeptember 12, 2026 | insidertrades.com$20,000 gold before year end?President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story. | Stansberry Research (Ad)Wall Street Zen Upgrades Aquestive Therapeutics (NASDAQ:AQST) to "Hold"September 12, 2026 | americanbankingnews.comAquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into FocusSeptember 8, 2026 | finance.yahoo.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 7, 2026 | americanbankingnews.comAquestive Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 1, 2026 | globenewswire.comAquestive Therapeutics, Inc. (AQST)August 22, 2026 | finance.yahoo.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $6.46 at the start of the year. Since then, AQST stock has decreased by 25.5% and is now trading at $4.81. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.08. The business earned $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $68 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,500,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Top institutional shareholders of Aquestive Therapeutics include Bratton Capital Management L.P. (7.82%), BlackRock Inc. (6.43%), Bank of America Corp DE (1.33%) and Wasatch Advisors LP (1.10%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender, A Ernest Toth Jr, Peter E Boyd, Carl N Kraus, Cassie Jung, Melina Cioffi, Sherry Korczynski and Julie Krop. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE). Company Calendar Last Earnings8/11/2026Today9/16/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AQST's financial health is in the Green zone, according to TradeSmith. AQST has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees147Year Founded2004Price Target and Rating Average Price Target for Aquestive Therapeutics$9.17 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+90.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.78 million Net Margins-144.63% Pretax Margin-144.63% Return on EquityN/A Return on Assets-52.40% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio6.74 Sales & Book Value Annual Sales$44.54 million Price / Sales13.55 Cash FlowN/A Price / Cash FlowN/A Book Value($0.28) per share Price / Book-17.18Miscellaneous Outstanding Shares125,510,000Free Float116,965,000Market Cap$603.70 million OptionableOptionable Beta1.48 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AQST) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
